- Home
- EU vs PHAR Comparison
EU vs PHAR Comparison
Compare EU & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EU | PHAR |
|---|---|---|
| Founded | 2009 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 501.9M | 1.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EU | PHAR |
|---|---|---|
| Price | $2.63 | $17.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $4.00 | ★ $38.00 |
| AVG Volume (30 Days) | ★ 2.9M | 22.5K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.00 |
| Revenue | $44,142,000.00 | ★ $362,274,000.00 |
| Revenue This Year | $22.24 | $24.80 |
| Revenue Next Year | $86.15 | $6.84 |
| P/E Ratio | ★ N/A | $2,946.57 |
| Revenue Growth | N/A | ★ 26.78 |
| 52 Week Low | $1.01 | $7.50 |
| 52 Week High | $4.19 | $18.12 |
Technical Indicators
Market Signals| Indicator | EU | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 48.91 | 58.26 |
| Support Level | $2.28 | $16.15 |
| Resistance Level | $2.46 | $17.00 |
| Average True Range (ATR) | 0.20 | 0.75 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 44.03 | 82.25 |
Price Performance
Historical ComparisonAbout EU enCore Energy Corp.
enCore Energy Corp together with its subsidiary, is engaged in the acquisition and exploration of resource properties of uranium resource properties in the United States. The holds a portfolio of uranium assets located in New Mexico, South Dakota, Wyoming, Texas, Utah, Colorado, and Arizona in the USA, and is advancing its properties with a focus on utilizing in-situ recovery. The company's Projects are South Texas Operations, Dewey-Burdock Project, Gas Hills Project, Crownpoint & Hosta Butte Project, PFN (Prompt Fission Neutron) Technology, and Other Assets.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.